Aortic aneurysm

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member

Retrieved on: 
Thursday, February 1, 2024
Emerald, Multimedia, Surgeon, Ageing, Knowledge, Aneurysm, Family, Vein, Henry Ford Hospital, Artery, Varicose veins, Southern Methodist University, Society, Patient, Philosophy, ABS, Hartford Hospital, Mentorship, Council, Aortic aneurysm, Medical degree, Journal, Dialysis, Education, Moyamoya disease, Methodist University, Stroke, Blood, Peripheral artery disease, University, Inner circle, Private practice, Nursing

PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysms; and peripheral artery disease surgery.

Life Line Screening Announces Expansion of 250+ Preventive Heart Health and Stroke Risk Screening Events for 2024

Retrieved on: 
Monday, January 8, 2024
Technology, Men, Managed Care, General Health, Science, Consumer, Cardiology, Other Communications, Health, Other Science, Research, Other Technology, Telemedicine, Virtual Medicine, Communications, Other Health, Women, Seniors, Life Line Screening, Stroke, Peripheral artery disease, Lifeline, Risk, Multimedia, Aortic aneurysm, Atrial fibrillation, History

Life Line Screening, the nation's leading provider of mobile preventive heart health and stroke risk screenings announced their expansion of cardiovascular screening events to more local communities throughout the United States for 2024.

Key Points: 
  • Life Line Screening, the nation's leading provider of mobile preventive heart health and stroke risk screenings announced their expansion of cardiovascular screening events to more local communities throughout the United States for 2024.
  • This expansion will bring the number of nationwide preventive health screening events to over 14,800, which will support approximately 700,000 people with understanding their cardiovascular health, risk of stroke, and more through Life Line Screening’s community-based ultrasound and phlebotomy testing.
  • More about Life Line Screening:
    Life Line Screening is the nation’s leading preventive health screening platform.
  • Life Line Screening's preventive health events are centered around vascular health, stroke prevention, metabolic health, oncology testing, and more.

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
Monday, January 8, 2024
RNA, JW Marriott Hotels, Protein, Neoplasm, Tumor microenvironment, Atherosclerosis, Messenger, WNT16, Aortic aneurysm, SOD2, Tissue, Osteoarthritis, Therapy, DNMT3B, Rheumatoid arthritis, Inflammation, Cancer, Semaphore, Vaccine

HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.

Key Points: 
  • Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
    HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
  • Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”.
  • “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date.
  • SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46).

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member for his contributions to the Vascular Surgery Field

Retrieved on: 
Wednesday, October 25, 2023
Emerald, Knowledge, Stroke, Peripheral artery disease, Artery, Education, Ageing, Council, National Council on Aging, Vein, Aortic aneurysm, American Board of Commissioners for Foreign Missions, American Board of Surgery, Varicose veins, PANAMA, Mentorship, Multimedia, ABS, Medical degree, Dialysis, Inner circle, Henry Ford Hospital, Surgeon, Methodist University, Southern Methodist University, Moyamoya disease, University, Blood, Society, Patient, Hartford Hospital, Dentistry, Nursing, Science, MD, Biology, Chemistry

PANAMA CITY, Fla., Oct. 25, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla., Oct. 25, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysm; and peripheral artery disease surgery.

Alcami Supports Phase II/III Trial Supply of the Nectero EAST® System

Retrieved on: 
Tuesday, October 17, 2023
Rupture, Food, Aortic aneurysm, Risk, IND, AAA, Elastin, PGG, Patient, CGMP, Growth, Journal, Collagen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDMO, Pharmaceutical industry, Medical device

Nectero Medical is developing a novel treatment to stabilize growth and potentially prevent rupture of smaller AAA.

Key Points: 
  • Nectero Medical is developing a novel treatment to stabilize growth and potentially prevent rupture of smaller AAA.
  • The Nectero EAST System is comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG).
  • "Nectero Medical is addressing the over 1,000,000 patients in the US with an AAA and currently no method of treatment.
  • Nectero EAST® is a registered trademark of Nectero Medical.

Leading International Cardiothoracic Surgeon & Researcher Named System Director of Aortic Surgery at NYU Langone Health

Retrieved on: 
Thursday, August 3, 2023
University, Education, NYU Langone Health, NYU, Cardiovascular disease, New York University Grossman School of Medicine, Aortic aneurysm, MBA, Research, Doctor of Philosophy, Science, St. Michael's Hospital, Patient, Division, Pediatrics, Unity Health Toronto, Michael (archangel), Faculty, Hospital, Saint Michael, Dentistry, Brain, MD

NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Mark D. Peterson, MD, PhD, an internationally recognized cardiothoracic surgeon and researcher, has been named system director of aortic surgery at NYU Langone Heart and professor in the Department of Cardiothoracic Surgery at NYU Grossman School of Medicine, effective August 1.

Key Points: 
  • NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Mark D. Peterson, MD, PhD, an internationally recognized cardiothoracic surgeon and researcher, has been named system director of aortic surgery at NYU Langone Heart and professor in the Department of Cardiothoracic Surgery at NYU Grossman School of Medicine, effective August 1.
  • "His clinical skill in complex aortic surgery, his commitment to patient outcomes, and his dedication to training future cardiothoracic surgeons align with the core mission of the Department of Cardiothoracic Surgery.
  • Within NYU Langone Heart, Dr. Peterson will work with a team of multidisciplinary specialists who address and determine the best treatments for aortic disease.
  • At NYU Langone's Center for Complex Aortic Disease , renowned cardiothoracic and vascular experts bring together their decades of surgical expertise to repair the hardest-to-treat types of aortic aneurysm, including aortic root, aortic arch, and thoracoabdominal aneurysms.

The Inner Circle Acknowledges, Patrick Tamim as a Top Pinnacle Professional for his contributions to the Vascular Surgery Field

Retrieved on: 
Friday, July 28, 2023
Emerald, Moyamoya disease, Surgeon, Society, University, Vein, Education, National Council on Aging, Stroke, Varicose veins, Southern Methodist University, Multimedia, Artery, Mentorship, Inner circle, Dialysis, Blood, Ageing, ABS, American Board of Commissioners for Foreign Missions, Patient, Council, Peripheral artery disease, Methodist University, Knowledge, American Board of Surgery, Hartford Hospital, Medical degree, Henry Ford Hospital, Aortic aneurysm, PANAMA, Dentistry, Nursing, Science, MD, Chemistry, Biology

PANAMA CITY, Fla., July 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Top Pinnacle Professional for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla., July 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Top Pinnacle Professional for his contributions to the Vascular Surgery Field.
  • Dr. Tamim pursued higher education at Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut to complete his higher education.
  • In the field since 2010, the doctor provides treatment for carotid disease; aortic aneurysm; and peripheral artery disease surgery.

Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease

Retrieved on: 
Tuesday, July 18, 2023
Health, Medical Devices, Surgery, Other Health, General Health, Cardiology, Biotechnology, Femoral vein, PAD, PTAB, Leg, Multimedia, Aortic aneurysm, MD, Patient, Physician, Moyamoya disease, Vascular disease, FDA, Arnold, Stent, Medical imaging

“We are delighted to be able to introduce PTAB using the DETOUR System into clinical use,” said Matt Thompson, MD, President, and CEO of Endologix LLC.

Key Points: 
  • “We are delighted to be able to introduce PTAB using the DETOUR System into clinical use,” said Matt Thompson, MD, President, and CEO of Endologix LLC.
  • "The DETOUR System is a pivotal addition to our product portfolio, which now offers differentiated therapies for both abdominal aortic aneurysms and PAD.
  • The successful introduction at these leading institutions underscores our commitment to continuing to innovate on behalf of patients.
  • Broadening our therapeutic profile is a key achievement as we transform Endologix into a leading interventional vascular company.”

Illuminate Addresses Gender and Racial Inequities in Aneurysm Care

Retrieved on: 
Thursday, June 8, 2023
Aortic aneurysm, Workflow, Aneurysm, Health equity, Woman, Coronary artery aneurysm, Patient, EHR, Guideline, Disease, Illuminate, Diagnosis, Mortality, VAM, Safety, Pharmaceutical industry, Customer service

OVERLAND PARK, Kan., June 8, 2023 /PRNewswire/ --Softek Illuminate, Inc., provider of enterprise follow-up management and discovery software, announces significant arterial aneurysm enhancements which allow the comprehensive life-saving capability of their Illuminate Discovery360TM Platform which benefits all at-risk aneurysm populations. One real world example of this life saving technology that also ensures health equity, is the Aortic Aneurysm program at UCDavis Health.

Key Points: 
  • Leveraging new comprehensive arterial aneurysm surveillance capabilities to fully automate the identification and management of aneurysm patients.
  • OVERLAND PARK, Kan., June 8, 2023 /PRNewswire/ -- Softek Illuminate, Inc. , provider of enterprise follow-up management and discovery software, announces significant arterial aneurysm enhancements which allow the comprehensive life-saving capability of their Illuminate Discovery360TM Platform which benefits all at-risk aneurysm populations.
  • One real world example of this life saving technology that also ensures health equity, is the Aortic Aneurysm program at UCDavis Health .
  • They provide examples of how our people, process and technology can be used to uncover and resolve gender and racial inequities:

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

Retrieved on: 
Tuesday, May 23, 2023
Surgery, Hospitals, Clinical Trials, Cardiology, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Gauge, JAGUAR, Metaphilosophy, Aortic aneurysm, AAA, Patient, Randomized controlled trial, Vascular disease, EVAR, Medical imaging

This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).

Key Points: 
  • This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).
  • The JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization) Study is a prospective, randomized, multi-center study, designed to enroll 450 patients at up to 60 sites.
  • "This milestone for Endologix underlines our dedication to clinical research and patient care," stated Matt Thompson, President, and CEO of Endologix.
  • “The JAGUAR trial, our second randomized study aimed at assessing comparative endograft performance, follows in the footsteps of our successful LEOPARD study.